Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume – What’s Next?

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) saw unusually-strong trading volume on Wednesday . Approximately 6,686,839 shares traded hands during trading, an increase of 168% from the previous session’s volume of 2,494,439 shares.The stock last traded at $10.6120 and had previously closed at $10.69.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RLAY shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, January 9th. Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a research report on Monday, January 26th. Finally, Wells Fargo & Company lifted their target price on Relay Therapeutics from $13.00 to $15.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.40.

Relay Therapeutics Stock Performance

The stock’s 50 day moving average price is $8.58 and its 200 day moving average price is $7.09. The company has a market capitalization of $1.90 billion, a P/E ratio of -6.55 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last announced its earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The firm had revenue of $7.00 million for the quarter, compared to the consensus estimate of $4.34 million. On average, analysts expect that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Donald A. Bergstrom sold 18,895 shares of the company’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the sale, the insider owned 422,733 shares in the company, valued at $3,221,225.46. This represents a 4.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas Catinazzo sold 13,820 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total value of $105,308.40. Following the completion of the sale, the chief financial officer owned 250,996 shares of the company’s stock, valued at approximately $1,912,589.52. The trade was a 5.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,302 shares of company stock valued at $724,355 over the last 90 days. 4.32% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of RLAY. Torren Management LLC acquired a new stake in Relay Therapeutics in the fourth quarter worth $30,000. Quinn Opportunity Partners LLC acquired a new position in shares of Relay Therapeutics during the second quarter valued at about $35,000. Smartleaf Asset Management LLC boosted its position in shares of Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after purchasing an additional 3,287 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Relay Therapeutics by 245.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 11,791 shares of the company’s stock valued at $41,000 after buying an additional 8,374 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Relay Therapeutics in the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.